Keyphrases
Nivolumab
100%
Stereotactic Body Radiotherapy
95%
Ipilimumab
89%
Phase II Study
72%
Randomized Phase II Trial
70%
Capecitabine
68%
Immune Checkpoint Inhibitors
54%
Tocilizumab
45%
Metastatic Pancreatic Cancer
45%
Pancreatic Ductal Adenocarcinoma
45%
Irinotecan
45%
Oral Administration
45%
Cancer Patients
45%
Tolerability
45%
Confidence Interval
31%
Maximum Tolerated Dose
31%
Pancreatic Cancer
30%
Clinical Benefit Rate
30%
Oral Irinotecan
29%
IL-6 Blockade
28%
Gemcitabine
28%
Radiotherapy
27%
YKL-40
27%
Checkpoint Inhibitors
27%
Solid Tumors
26%
Randomized Controlled Trial
22%
Cancer nurse
22%
Decision-making Roles
22%
Cancer Physicians
22%
Checkpoint Inhibitor Colitis
22%
Exercise Intervention
22%
Biliary Tract Cancer
22%
Arthritis
22%
Immune-related Proteins
22%
Study Evaluation
22%
Multimodal Exercise
22%
Patients with Advanced Cancer
22%
Older Patients
22%
Fas Ligand
22%
Chemotherapy Side Effects
22%
Age-related Differences
22%
Old Age
22%
Placebo
22%
Oxaliplatin
22%
Resection
22%
Treatment Refractory
22%
Adjuvant Therapy
22%
Dose Escalation
22%
Metastatic Colorectal Cancer (mCRC)
22%
Cognitive Screening
22%
Medicine and Dentistry
Stereotactic Body Radiation Therapy
100%
Nivolumab
98%
Pancreas Cancer
93%
Ipilimumab
89%
Immune Checkpoint Inhibitor
68%
Malignant Neoplasm
48%
Tocilizumab
45%
Cancer Therapy
35%
Pancreas Adenocarcinoma
34%
Neoplasm
29%
Gemcitabine
28%
Progression Free Survival
27%
Radiation Therapy
26%
Adverse Event
25%
Overall Survival
23%
Immunotherapy
23%
Randomized Controlled Trial
22%
Interleukin-6
22%
Colitis
22%
Adjuvant Therapy
22%
Biliary Tract Cancer
22%
Castration Resistant Prostate Cancer
22%
Side Effect
22%
Metastatic Colorectal Cancer
22%
Placebo
22%
Clinical Study
22%
Capecitabine
22%
Advanced Cancer
22%
Arthritis
22%
Phase II Trials
22%
Quality of Life
20%
Glucocorticoid
19%
Fas Ligand
18%
Symptom
18%
Arm
16%
Galectin 1
15%
Disease
13%
Targeted Therapy
11%
Prostate Specific Antigen
11%
Progressive Disease
11%
Oncology
11%
Surgery
11%
Biological Marker
10%
Interleukin 6
10%
Health Status
7%
Immunoglobulin
7%
Next Generation Sequencing
7%
Nurse
7%
Genome Sequencing
7%
Exercise
7%
Pharmacology, Toxicology and Pharmaceutical Science
Pancreas Cancer
93%
Immune Checkpoint Inhibitor
68%
Capecitabine
68%
Nivolumab
64%
Ipilimumab
60%
Tocilizumab
45%
Irinotecan
45%
Tolerability
45%
Chemotherapy
37%
Malignant Neoplasm
35%
Pancreas Adenocarcinoma
34%
Adverse Event
29%
Gemcitabine
28%
Maximum Tolerated Dose
27%
Solid Malignant Neoplasm
25%
Pharmacokinetics
25%
Side Effect
25%
Overall Survival
24%
Disease
24%
Colitis
22%
Arthritis
22%
Placebo
22%
Clinical Study
22%
Oxaliplatin
22%
Breast Cancer
22%
Liver Metastasis
22%
Progression Free Survival
22%
Glucocorticoid
19%
Fas Ligand
18%
Immunotherapy
17%
Galectin 1
15%
Diarrhea
14%
Neoplasm
14%
Metastatic Breast Cancer
12%
Biological Marker
10%
Interleukin 6
10%
Disease Free Survival
7%
Immunoglobulin
7%
Remission
6%
Metastasis
6%
Syndrome
5%
Cholinergic Receptor Stimulating Agent
5%
Tumor Microenvironment
5%
Fluorouracil
5%
Antitumor Activity
5%
Comorbidity
5%